Researchers at the University of California, Davis have developed a viral peptide therapeutic that targets MYC-based cancerous tumors.
Researchers at the University of California Davis have developed a cancer therapeutic based on an oncogenic virus. This treatment directly inhibits cancerous gene expression, preventing the genes from replicating. Thus, MYC-based tumors are targeted and destroyed. The drug has also shown impressive results in eliminating lymphomas in xenograft studies on mice, killing the cancer cells without any toxicity to the host.
|Patent Cooperation Treaty||Reference for National Filings||WO 2022/087221||04/08/2022||2020-557|
cancer therapeutic, MYC, viral oncology, viral peptide sequencing, oncology, peptide